Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TT-10 · 1 trial · 7 indications
All toxicities will be graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0
To confirm the maximum tolerated dose (MTD) of TT-10, TT-4 and TT-10 + TT-4, defined as the highest dose level at which \<2 out of 6 participants experience a dose-limiting toxicity
Incidence and severity of treatment-related adverse events (TRAEs) in participants treated at the recommended phase 2 dose in the expansion phase
| Arm | Type | Description |
|---|---|---|
| Cohort A: Dose Escalation | EXPERIMENTAL | Drug: TT-10 (A2A Receptor Antagonist) * Supplied in capsules for daily oral administration twice a day (BID) * One cycle is considered 28 days * Ascending Dose levels are being explored * Dose Level 1 * Dose Level 2 * Dose Level 3 * Dose Level 4\* \*Additional dose levels may be explored, if appropriate based on emerging safety, PK or pharmacodynamic data |
| Cohort B: Dose Escalation | EXPERIMENTAL | Drug: TT-4 (A2B Receptor Antagonist) * Supplied in capsules for daily oral administration once a day (QD) * One cycle is considered 28 days * Ascending Dose levels are being explored * Dose Level 1 * Dose Level 2 * Dose Level 3\* * \*Additional dose levels or frequency may be explored, if appropriate based on emerging safety, PK or pharmacodynamic data |
| Cohort C: Dose Escalation | EXPERIMENTAL | Drugs: TT-10 + TT-4 - Dual Receptor Antagonists * Both drugs will be supplied in capsules for daily oral administration and administered separately. * One cycle is considered 28 days * Ascending Dose levels of both drugs are being explored and will be determined after safety review of Cohorts A and B |
| Name | Type | Description |
|---|---|---|
| TT-10 | DRUG | TT-10 orally administered BID |
| TT-4 | DRUG | TT-4 is orally administered QD |
To be eligible for inclusion in the dose escalation cohorts or expansion cohorts in this study, participants must meet all of the following criteria: 1. Participants must be ≥18 years of age. 2. Participants or their legal representative must be able to provide written informed consent to participa...
TT-10 is an investigational small molecule being developed for the treatment of Renal Cell Cancer. It is also being studied in other advanced solid tumors, including Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Endometrial Cancer, and Ovarian Cancer.
TT-10 is being developed by AlphaTON Capital Corp. (ticker: ATON). The company is currently conducting clinical trials to evaluate the safety and efficacy of TT-10 in patients with advanced solid tumors.
TT-10 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy.
TT-10 is being studied in a Phase 1 clinical trial with the identifier NCT04969315. This trial evaluates TT-10 (PORT-6) and TT-4 (PORT-7) as single agents and in combination in subjects with advanced selected solid tumors. The trial is recruiting in the United States with an enrollment of 90 participants.
Yes, TT-10 is also known as PORT-6. The clinical trial NCT04969315 refers to TT-10 as PORT-6, indicating that these names are used interchangeably for the same investigational drug.